A phase 3 trial found that Eli Lilly’s tirzepatide significantly reduced the risk of progression to Type 2 diabetes in prediabetic adults over a three-year period. Nearly 99% of individuals treated with tirzepatide remained diabetes-free by the end of the study.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
